Two subunit vaccines targeting the pre-erythrocytic stage of malaria have demonstrated limited protective immunity in humans, RTS,S and ME-TRAP (based on the antigens CSP and TRAP, respectively). This evidence concerns the gene DNAJC5 and malaria.